DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Filanesib
Filanesib
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
A Phase 1 Dose-Escalation Study of Filanesib Plus
Pomalidomide Enhanced Gemcitabine and Nab-Paclitaxel on Pancreatic Cancer Both in Vitro and in Vivo
Daratumumab (Darzalex)
Novel Targets in Multiple Myeloma
Salvage Therapies in Relapsed And/Or Refractory Myeloma: What Is Current and What Is the Future?
Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients with Recurrent/Refractory Multiple Myeloma
Belantamab Mafodotin to Treat Multiple Myeloma: a Comprehensive Review of Disease, Drug Efficacy and Side Effects
Patient Case and Question
(Filanesib) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low Α‐1 Acid Glycoprotein (AAG) Levels: Results from a Phase 2 Study
Experimental Therapies for Relapsed Myeloma
Management of Multiple Myeloma: the Changing Paradigm
Advances in the Management of Myeloma
POMALYST® (Pomalidomide) Prescribing Information
Salvage Therapy of Multiple Myeloma: the New Generation Drugs
Myeloma and Other Monoclonal Gammopathies - Dosis
New Investigational Drugs with Single-Agent Activity in Multiple Myeloma
DEPARTMENT of MEDICINE 2014 Annual Report
Top View
Leukemia Lymphoma Myeloma 5Th International Congress
(Filanesib) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low Α‐1 Acid Glycoprotein (AAG) Levels: Results from a Phase 2 Study
A Selective Inhibitor of Kinesin Spindle Protein, for Patients with Relapsed/ Refractory MM
Magic Year for Multiple Myeloma Therapeutics: Key Takeaways from the ASH 2015 Annual Meeting
Drug Targets and Resistance Mechanisms in Multiple Myeloma
Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed And/Or Refractory Multiple Myeloma (RRMM)
Refractory Multiple Myeloma: Increased Options and Increased Complexity